|
• Diagnosis of cirrhosis
|
• West Haven score of ≥2 at study entry
|
|
• Age ≥ 18 years
|
• A mental health disorder that makes HE diagnosis questionable (e.g., dementia, psychosis)
|
|
• Enrolment within 12 weeks of resolution of an episode of overt HE associated with a hospital visit
|
• Prior treatment with rifaximina within 12 months prior to the qualifying overt HE episode
|
|
• Ability to provide informed consent
|
• Contraindications to the use of rifaximin-α 550 mg, as per the local Summary of Product Characteristics [16, 17]
|
|
• Clinical eligibility to receive rifaximin-α 550 mg, in the opinion of the participating physician, regardless of HE treatment actually received
| |
